search

Active clinical trials for "Hyperplasia"

Results 921-926 of 926

Storage Symptom After Laser Prostatectomy

Prostatic Hyperplasia

Recent literature indicated that postoperative storage symptoms after Photoselective vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP) were often reported and generally more common than after transurethral prostatectomy (TURP). However, almost all literature focused on postoperative urgency or dysuria immediately after PVP or HoLEP. Thus, there has been a scarcity of data on serial changes of storage symptoms in the postoperative period after PVP or HoLEP and data on predicting factors that influence improvement in storage symptoms postoperatively. The aim of this study was to compare serial changes of postoperative storage symptoms between PVP and HoLEP, and to identify the predictors that influence improvement of storage symptoms postoperatively.

Unknown status4 enrollment criteria

Genetic Identification (ID) of Segmental Dysplastic Nevi

Segmental Dysplastic Nevi

The investigators' goal is to identify the mutation in the gene that is responsible for the development of segmental dysplastic nevi. To identify the gene the investigators may use a candidate gene approach (i.e. sequence specific genes that are thought to be involved: NRAS, BRAF, etc) or a genome-wide approach trying to implicate regions in the genome (Loss-of-heterozygosity or copy number changes on comparative genomic hybridization).

Unknown status2 enrollment criteria

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma...

Prostate CancerBenign Prostatic Hyperplasia1 more

Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that: ANXA3 can be detected in urine after standard digital rectal examination. ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA ANXA3 can help avoid unnecessary biopsies ANXA3 can in the long run replace PSA as a marker

Unknown status4 enrollment criteria

TURP; Complications and Outpatient Care

Benign Prostatic Hyperplasia

This study aims to investigate the impact of transurethral prostate resection in regard to complications. These are direct surgical complications, such as bleeding, infection and readmissions, as well as the long term complications as incontinence and impotence. Also, the study aims to investigate if selected cases of patients could be performed as outpatient surgery, thereby reducing cost.

Unknown status2 enrollment criteria

Early Detection of Prostate Cancer by FACS

Prostate CancerHyperplasia

Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.

Unknown status7 enrollment criteria

Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy

Prostatic Hyperplasia

The aim of this study was to evaluate an impact of preoperative bladder underactivity on treatment outcomes of photoselective vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic obstruction, and to compare it between the two types of surgery for benign prostatic hyperplasia.

Unknown status5 enrollment criteria
1...9293

Need Help? Contact our team!


We'll reach out to this number within 24 hrs